Research programme: pain and neurological disorder therapeutics - CSIRO/NeuroDiscovery

Drug Profile

Research programme: pain and neurological disorder therapeutics - CSIRO/NeuroDiscovery

Latest Information Update: 16 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuroDiscovery
  • Developer CSIRO; NeuroDiscovery
  • Class
  • Mechanism of Action Gap junction modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Neuralgia; Neurological disorders; Pain

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top